Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
Heidari, Mahnaz
Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. [electronic resource] - International clinical psychopharmacology Nov 2014 - 344-50 p. digital
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1473-5857
10.1097/YIC.0000000000000043 doi
Adolescent
Adult
Double-Blind Method
Drug Therapy, Combination
Female
Fluvoxamine--adverse effects
Humans
Male
Middle Aged
Obsessive-Compulsive Disorder--drug therapy
Ondansetron--adverse effects
Placebos
Serotonin Antagonists--adverse effects
Selective Serotonin Reuptake Inhibitors--adverse effects
Treatment Outcome
Young Adult
Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. [electronic resource] - International clinical psychopharmacology Nov 2014 - 344-50 p. digital
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1473-5857
10.1097/YIC.0000000000000043 doi
Adolescent
Adult
Double-Blind Method
Drug Therapy, Combination
Female
Fluvoxamine--adverse effects
Humans
Male
Middle Aged
Obsessive-Compulsive Disorder--drug therapy
Ondansetron--adverse effects
Placebos
Serotonin Antagonists--adverse effects
Selective Serotonin Reuptake Inhibitors--adverse effects
Treatment Outcome
Young Adult